S. Mustjoki, S. Hernesniemi, A. Rauhala, M. Kahkonen, A. Almqvist et al., A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34), Haematologica, vol.94, issue.10, pp.1469-1471, 2009.
DOI : 10.3324/haematol.2009.008094

K. Inokuchi, S. Wakita, T. Hirakawa, H. Tamai, N. Yokose et al., RCSD1-ABL1-positive B lymphoblastic leukemia is sensitive to dexamethasone and tyrosine kinase inhibitors and rapidly evolves clonally by chromosomal translocations, International Journal of Hematology, vol.21, issue.3, pp.255-260, 2011.
DOI : 10.1007/s12185-011-0910-z

D. Braekeleer, E. Douet-guilbert, N. Guardiola, P. Rowe, D. Mustjoki et al., Acute lymphoblastic leukemia associated with RCSD1???ABL1 novel fusion gene has a distinct gene expression profile from BCR???ABL1 fusion, Leukemia, vol.35, issue.6, pp.1422-1424, 2013.
DOI : 10.1038/leu.2012.332

M. Loosveld, R. Castellano, S. Gon, A. Goubard, T. Crouzet et al., Therapeutic Targeting of c-Myc in T-Cell Acute Lymphoblastic Leukemia (T-ALL), Oncotarget, vol.5, issue.10, pp.3168-3172, 2014.
DOI : 10.18632/oncotarget.1873

M. Ren, H. Qin, R. Ren, and J. Cowell, Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities, Leukemia, vol.178, issue.1, pp.32-40, 2013.
DOI : 10.1038/nrc1590

J. Cortes, H. Kantarjian, N. Shah, D. Bixby, M. Mauro et al., Ponatinib in Refractory Philadelphia Chromosome???Positive Leukemias, New England Journal of Medicine, vol.367, issue.22, pp.2075-2088, 2012.
DOI : 10.1056/NEJMoa1205127

T. Hare, W. Shakespeare, X. Zhu, C. Eide, V. Rivera et al., AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance, Cancer Cell, vol.16, issue.5, pp.401-412, 2009.
DOI : 10.1016/j.ccr.2009.09.028

T. Zhou, L. Commodore, W. Huang, Y. Wang, M. Thomas et al., Structural Mechanism of the Pan-BCR-ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance, Chemical Biology & Drug Design, vol.50, issue.1, pp.1-11, 2011.
DOI : 10.1111/j.1747-0285.2010.01054.x

P. Filippakopoulos, M. Kofler, O. Hantschel, G. Gish, F. Grebien et al., Structural Coupling of SH2-Kinase Domains Links Fes and Abl Substrate Recognition and Kinase Activation, Cell, vol.134, issue.5, pp.793-803, 2008.
DOI : 10.1016/j.cell.2008.07.047

T. Pemovska, M. Kontro, B. Yadav, H. Edgren, S. Eldfors et al., Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia, Cancer Discovery, vol.3, issue.12, pp.1416-1429, 2013.
DOI : 10.1158/2159-8290.CD-13-0350

K. Roberts, Y. Li, D. Payne-turner, R. Harvey, Y. Yang et al., Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia, New England Journal of Medicine, vol.371, issue.11, pp.1005-1015, 2014.
DOI : 10.1056/NEJMoa1403088